Intranasal corticosteroids do not affect intraocular pressurec or lens opacity: A systematic review of controlled trials

Rhinology

Volumn 53, Issue 4, 2015, Pages 290-302

  Ahmadi, Nazanin ^a   Snidvongs, Kornkiat ^d   Kalish, Larry ^c   Sacks, Raymond ^b,c   Tumuluri, Krishna ^e   Wilcsek, Geoff ^a   Harvey, Richard ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Cataract; Chronic upper airway disease; Glaucoma; Intranasal steroids; Intraocular pressure

Indexed keywords

CORTICOSTEROID;

CATARACT; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; CATARACT; HUMANS; INTRAOCULAR PRESSURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84953708469     PISSN: 03000729     EISSN: 19968604     Source Type: Journal    
DOI: 10.4193/Rhino15.020     Document Type: Article

References (43)

1. Garbe E, LeLorier J, Boivin J-F, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997; 277(9):722-7.
2. Barnes N. Safety of high-dose inhaled cortisubcapsular costeroids. Resp Med. 1993;87:27-31.
3. Garbe E, LeLorier J, Boivin J-F, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350(9083):979-82.
4. Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. AmJ Otolaryngol. 2008;29(6):403-13.
5. Bonfils P, Norès JM, Halimi P, Avan P. Corticosteroid Treatment in Nasal Polyposis With a Three-Year Follow-Up Period. Laryngoscope. 2003;113(4):683-7.
6. Seiberling KA, Chang DF, Nyirady J, Park F, Church CA, editors. Effect of intranasal budesonide irrigations on intraocular pressure. Int Forum Allergy Rhinol. 2013;3(12):953-7.
7. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12.
8. Rudmik L, Hoy M, Schlosser RJ, et al., editors. Topical therapies in the management of chronic rhinosinusitis: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(4):281-98.
9. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-300.
10. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2006 Apr;96(4):514-25.
11. Bui CM, Chen H, Shyr Y, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol. 2005;116(5):1042-7.
12. Liu A, Manche EE. Bilateral posterior subcapsular cataracts associated with longterm intranasal steroid use. J Cataract Refract Surg. 2011;37(8):1555-8.
13. Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102(2):177-9.
14. Oztürk F, Yücetürk A, Kurt E, Unlü H, Ilker S. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear, Nose, Throat J. 1998;77(10):846-8.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009;151(4):264-9.
16. Fokkens WJ, Lund VJ, Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology Supplement. 2006 (20):1-136.
17. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg. 2003;129(3):S1-S32.
18. Snidvongs K, Heller GZ, Sacks R, Harvey RJ. Validity of European Position Paper on Rhinosinusitis Disease Control Assessment and Modifications in Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2013:0194599813517080.
19. Higgins J, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343.
20. Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, Arrieta-Gomez JR, Astorga Del Toro R, Bravo-Escobar G. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg. 2004;130(2):187-91.
21. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(5):657-63.
22. Rotenberg BW, Zhang I, Arra I, Payton KB. Postoperative care for Samter ’s triad patients undergoing endoscopic sinus surgery: A double-blinded, randomized controlled trial. Laryngoscope. 2011;121(12):2702-5.
23. Yuen D, Buys YM, Jin Y-P, Alasbali T, Trope GE. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma. J Glaucoma. 2013;22(2):84-7.
24. Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, Mela EK, Goumas PD, Gartaganis SP. The effect of nasal steroid administration on intraocular pressure. Ear Nose Throat J. 2007;86(7):394.
25. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 2000;105(5):912-6.
26. Chervinsky P, Kunjibettu S, Miller DL, Prenner BM, Raphael G, Hall N, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2007;99(1):69-76.
27. Rosenblut A, Bardin P, Muller B, et al. Longterm safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007;62(9):1071-7.
28. Máspero JF, Rosenblut A, Finn Jr A, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol-Head Neck Surg. 2008;138(1):30-7.
29. Meltzer EO, Tripathy I, Máspero JF, Wu W, Philpot E. Safety and Tolerability of Fluticasone Furoate Nasal Spray Once Daily in Paediatric Patients Aged 6–11 Years with Allergic Rhinitis. Clin Drug Investig. 2009;29(2):79-86.
30. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediat Otorhinolaryngol. 2009;73(5):651-7.
31. LaForce C, Journeay GE, Miller SD, et al. Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study. Ann Allergy Asthma Immunol. 2013;111(1):45-50.
32. Forwith KD, Chandra RK, Yun PT, Miller SK, Jampel HD. ADVANCE: A multisite trial of bioabsorbable steroid-eluting sinus implants. Laryngoscope. 2011;121(11):2473-80.
33. Ozkaya E, Ozsutcu M, Mete F. Lack of ocular side effects after 2 years of topical steroids for allergic rhinitis. J Pediatr Ophthalmol Strabismus. 2010;48(5):311-7.
34. Brookes JL, Khaw PT. Steroid response in children. Clin Experiment Ophthalmol. 2005;33(3):229-30.
35. Knutsson U, Stierna P, Marcus C, Carlstedt- Duke J, Carlström K, Brönnegård M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol. 1995;144(2):301-10.
36. Fraunfelder F, Meyer S. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Ophthalmol. 1990;109(4):489.
37. Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22(11):1458-67.
38. Black RL, Oglesby RB, von Sallmann L, Bunim JJ. Posterior subcapsular cataracts induced by cor ticosteroids in patients with rheumatoid arthritis. JAMA. 1960;174(2):166-71.
39. Kewley GD. Possible association between beclomethasone diproprionate aerosol and cataracts. J Paediat Child Health. 1980;16(2):117-8.
40. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337(1):8-14.
41. Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Resp Dis Suppl. 1981;122:86-95.
42. Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985;26(2):170-5.
43. Kersey JP, Broadway DC. Corticosteroidinduced glaucoma: a review of the literature. Eye. 2006;20(4):407-16.